SyntekaBio

SyntekaBio Interest Expense

The Interest Expense of SyntekaBio (226330.KQ) as of Nov 16, 2026 is 7.23 B KRW. In the previous year, Interest Expense was 1.54 B KRW — a change of 370.43% (higher).

Interest Expense

7.23 BKRW

YoY

370.43%

Last updated:

Interest Expense of SyntekaBio is 2024 7.23 B KRW. Interest Expense of SyntekaBio was 2023 1.54 B KRW. It decreases by 370.43% higher compared to the previous year.

The SyntekaBio Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2017
-1.92 B KRW
Jan 1, 2018
6.70 B KRW
Jan 1, 2019
-17.77 B KRW
Jan 1, 2020
606.50 M KRW
Jan 1, 2021
-6.03 B KRW
Jan 1, 2022
7.09 B KRW
Jan 1, 2023
1.54 B KRW
Jan 1, 2024
7.23 B KRW
The SyntekaBio Interest Expense history
YEARInterest ExpenseYoY
7.23 BKRW+370.43%
1.54 BKRW-78.32%
7.09 BKRW-217.58%
-6.03 BKRW-1,093.61%
606.50 MKRW-103.41%
-17.77 BKRW-365.42%
6.70 BKRW-448.09%
-1.92 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Interest Expense of SyntekaBio is 7.23 B KRW in 2024.

Interest Expense of SyntekaBio changed from 1.54 B KRW to 7.23 B KRW, representing a 370.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — SyntekaBio

All Key Metrics — SyntekaBio